Interaction of non-adherent suspended neutrophils to complement opsonized pathogens: a new assay using optical traps.
Phagocytosis of opsonized pathogens by circulating non-adherent neutrophils is an essential step in host defense, which when overwhelmed contributes to sepsis. To investigate the role played by ligation of complement receptors CR3 and CR4 in non-adherent neutrophils, we designed a novel assay system utilizing dual optical traps, respectively, holding a suspended unactivated cell and presenting a specific ligand-coated bead to the cell surface. We chose anti-CD18 as an example ligand, mimicking the bacterial opsonizing complement fragment iC3b. Presentation of anti-CD18-coated beads elicited both pseudopodial protrusion and subsequent phagocytosis. This is in sharp contrast to previously reported responses of adherent neutrophils, which phagocytize opsonized particles without pseudopod formation. We used this same new assay to probe actomyosin pathways in the neutrophil's pseudopodial and phagocytic response. Disruption of actin or inhibition of myosin light-chain kinase dose-dependently reduced pseudopod formation and phagocytosis rates. In summary, i) the new dual trap assay can be used to study the responses of suspended neutrophils to a variety of ligands, and ii) in a first application of this technique, we found that local ligation of CR3/4 in unactivated neutrophils in suspension induces pseudopod formation and phagocytosis at that site, and that these events occur via an actomyosin-dependent pathway.
Suzuki
Tomoko
T
Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai 980-8574, Japan.
Yanai
Masaru
M
Kubo
Hiroshi
H
Kanda
Akio
A
Sasaki
Hidetada
H
Butler
James P
JP
D000328:Adult; D000906:Antibodies / Q000276:immunology*; D001381:Azepines / Q000494:pharmacology; D018821:CD18 Antigens / Q000276:immunology; D022081:Cell Surface Extensions / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D003931:Diacetyl / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008846:Micromanipulation / Q000295:instrumentation / Q000379:methods; D008863:Microspheres; D009219:Myosin-Light-Chain Kinase / Q000037:antagonists & inhibitors; D009281:Naphthalenes / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology / Q000276:immunology*; D009895:Opsonin Proteins / Q000276:immunology; D055095:Optics and Photonics / Q000295:instrumentation; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D011951:Receptors, Complement / Q000276:immunology
D000906:Antibodies; D001381:Azepines; D018821:CD18 Antigens; D004791:Enzyme Inhibitors; D009281:Naphthalenes; D009895:Opsonin Proteins; D011951:Receptors, Complement; C070571:ML 7; C004717:diacetylmonoxime; D009219:Myosin-Light-Chain Kinase; D003931:Diacetyl